Cenexi Services S.A.S.A.U.

Cenexi Services S. A. S. A.

U. is a French contract development and manufacturing organization (CDMO) specializing in the production and packaging of sterile pharmaceutical products, serving clients in the pharmaceutical and biotechnology sectors. Founded in 2004, Cenexi Services S. A.

S. A. U. operates as a contract development and manufacturing organization focusing on sterile pharmaceutical products.

The company was fully acquired by Gland Pharma Limited in November 2022 for EUR 120 million, enhancing Gland Pharma's presence in Europe. The current CEOs are Christophe Durand and Jim Mcpherson. Cenexi is a contract development and manufacturing organization (CDMO) that specializes in the production and packaging of sterile pharmaceutical products. The company offers a comprehensive range of services designed to meet the needs of pharmaceutical laboratories, providing solutions for both large-scale industrial production and smaller projects.

Cenexi's core offerings include the manufacture of various sterile dosage forms such as ampoules, vials, and prefilled syringes, as well as non-sterile forms including tablets, capsules, and syrups. Their services extend from early-stage product development to full-scale commercialization, seamlessly integrating with clients' operations to ensure compliance with industry standards. The company serves a diverse client base that includes innovative pharmaceutical companies and biotechnology firms across multiple geographical markets, including Europe and beyond. In the most recent year, 2023, Cenexi reported revenue of EUR 86,021,781.

90 with an EBITDA of EUR -5,397,340. 90. The company generates revenue primarily through contracts for outsourcing pharmaceutical development and manufacturing services, structured as B2B transactions with pharmaceutical companies. Cenexi engages clients for specific aspects of drug development, including formulation, production, and packaging, governed by detailed contractual agreements.

Revenue is derived from service fees tied to the volume and complexity of production runs, heavily supported by the company’s investment in facilities and technology, especially in the injectable segment. Following its acquisition by Gland Pharma Limited, Cenexi aims to leverage this funding to enhance its manufacturing capabilities and expand its geographic footprint in Europe. The company plans to develop new products tailored to market demands, although specific release dates are not disclosed. The strategic acquisition position allows Cenexi to explore opportunities to penetrate additional markets, particularly within Europe, as part of Gland Pharma's objectives to broaden its reach.